Filing Details

Accession Number:
0001317757-10-000020
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-08-06 13:00:00
Reporting Period:
2010-08-05
Filing Date:
2010-08-06
Accepted Time:
2010-08-06 16:00:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
792977 Amag Pharmaceuticals Inc. AMAG In Vitro & In Vivo Diagnostic Substances (2835) 042742593
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1296999 David Arkowitz C/O Amag Pharmaceuticals, Inc.
100 Hayden Avenue
Lexington MA 02421
Evp, Cfo And Cbo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-08-05 15,000 $0.00 16,886 No 4 C Direct
Common Stock Disposition 2010-08-05 15,750 $0.00 1,136 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Acquisiton 2010-08-05 15,000 $0.00 15,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,000 No 4 C Direct
Footnotes
  1. The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below.
  2. Not applicable.
  3. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading pan adopted by the reporting person.
  4. The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold on this day. The actual sales prices range from $31.387-$31.90. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
  5. Each restricted stock unit represents a contingent right to receive one share of common stock.
  6. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. The grant will vest as follows: 50% on August 5, 2010, 25% on August 5, 2011 and the remaining 25% on August 5, 2012.